Friday, October 30, 2020 3:27:18 PM
RE: It is indeed a sad situation...
"A response of this magnitude has previously not been seen with an antiviral agent and is akin to the first reports of penicillin in treating pneumococcal pneumonia."
Not only will we all make a significant amount of gains, we also all will know more about this treatment than most. This is unlike any other investment I have... I feel like I am involved in saving the human race and have 1m on the line that has the potential to be a 50x bagger. Nothing any of us do say or think will change the process. Patience is all that is required, stay long -- smart money already has been doing that for a while.
Best,
JB
"A response of this magnitude has previously not been seen with an antiviral agent and is akin to the first reports of penicillin in treating pneumococcal pneumonia."
Not only will we all make a significant amount of gains, we also all will know more about this treatment than most. This is unlike any other investment I have... I feel like I am involved in saving the human race and have 1m on the line that has the potential to be a 50x bagger. Nothing any of us do say or think will change the process. Patience is all that is required, stay long -- smart money already has been doing that for a while.
Best,
JB
Disclaimer
All of my posts are just my own opinion and not advice to buy, sell or trade any stock, security or anything else for that matter. I post my own personal thoughts and information that I have found regarding positions that I am invested in.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
